LEIDEN, The Netherlands, September 10 The Danish Councilfor Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma)on Thursday, September 10. The purpose of their visit is to learn about theunique Dutch approach on public-private cooperation and the concrete resultsthat are being booked by this institute. In the past, in the EuropeanCouncil, Denmark has cited TI Pharma as a prime example of public-privatecollaboration in the pharmaceutical sector and is considering following itslead.
In Denmark, TI Pharma is seen as a role model of public-privatecooperation and partnership. "It is incredible how quickly TI Pharma hasbecome established and also what the institute has accomplished in its firstfew years. The Netherlands initiated a clear strategy to support innovativepharmaceutical research and the government had the courage to reward thisstrategy with implementation. In European pharmaceutical research, TI Pharmais a role model of public-private cooperation and partnership", says PerSpindler, Board of Directors of the Drug Information Association (DIA) andDirector of BioLogue/Danish Pharma Consortium (University of Copenhagen).[source: TI Pharma Annual Report 2008]
TI Pharma aims to develop the Netherlands into a European hotspot ininnovative pharmaceutical research. Willem de Laat, Managing Director of TIPharma: "We are excited to be able to share our experience and collaboratewith other European countries that want to support top quality public-privatepartnerships in the life sciences and health field in order to address themost important needs in public health."
The Danish Council for Strategic Research was established in 2004 as aninnovation within the Danish funding system for research. The Councilconsists of a Board and seven Programme Commissions. Within the Council,strategic research has a strong international dimension, with Danishscientists working closely together with the best international researchers.
SOURCE TI Pharma